Valuation: Eyebright Medical Technology (Beijing) Co., Ltd.

Market Cap 803.93Cr 118.57Cr 103.71Cr 96Cr 88Cr 167.64Cr 11TCr 170.46Cr 1.14TCr 448.84Cr 5.57TCr 445.18Cr 435.49Cr 19TCr P/E 2026 *
20.9x
P/E 2027 * 17.4x
Enterprise Value 769.36Cr 113.47Cr 99Cr 92Cr 85Cr 160.44Cr 11TCr 163.13Cr 1.09TCr 429.55Cr 5.33TCr 426.04Cr 416.77Cr 18TCr EV / Sales 2026 *
4.21x
EV / Sales 2027 * 3.45x
Free-Float
66.69%
Yield 2026 *
0.95%
Yield 2027 * 1.27%
03/07 UBS Downgrades Eyebright Medical Technology (Beijing) to Neutral from Buy; Price Target is 40 Yuan MT
12/06 Eyebright Medical Technology Co., Ltd.(SHSE:688050) dropped from Shanghai Stock Exchange Health Care Sector Index CI
31/05 Chaomu Technology Co., Ltd. announced that it has received funding from Zhongzhi Zhonghe, Lapam Capital, Aibo Hongsheng Equity Investment Fund Partnership (Limited Partnership), CDB Technology Venture Capital Co., Ltd., Eyebright Medical Technology Co., Ltd., Beijing Shunxi Venture Capital Fund Management Co.,Ltd. CI
22/04 Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
22/04 Eyebright Medical Technology Co., Ltd. announces Annual dividend, payable on June 22, 2026 CI
19/03 Eyebright Medical Technology Beijing Shareholder Plans to Trim Stake MT
27/02 Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/02 Eyebright Medical Technology to buy stake in medical tech firm RE
25/02 Eyebright Medical Technology Co., Ltd. agreed to acquire 68.31% stake in Delta Medical Technology Co., Ltd. from a group of shareholders for approximately CNY 680 million. CI
21/01 Eyebright Medical Technology Intends to Acquire Controlling Stake in Sports Medicine Company MT
30/25/30 Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/25/29 Eyebright Medical Technology Gets Marketing Approval for Intraocular Lens MT
27/25/27 Eyebright Medical Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
1 day+0.41%
1 week+4.06%
Current month+14.02%
1 month+4.08%
3 months-19.49%
6 months-35.83%
Current year-31.49%
1 week 37.6
Extreme 37.6
42.68
1 month 35.23
Extreme 35.23
42.68
Current year 35.23
Extreme 35.23
66.44
1 year 35.23
Extreme 35.23
83.83
3 years 35.23
Extreme 35.23
118
5 years 35.23
Extreme 35.23
183.31
10 years 35.23
Extreme 35.23
221.59
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 45 10/06/2019
Chief Executive Officer 54 21/04/2010
Director of Finance/CFO 47 01/01/2017
Director TitleAgeSince
Director/Board Member 41 19/06/2025
Chairman 54 21/04/2010
Director/Board Member 47 19/06/2025
Date Insider Type Main position Quantity % Market Cap.
30/25/30Buy

Public Communications Manager

9,450 0.0050%
24/24/24Buy

Director

5,457 0.0029%
27/24/27Buy

Founder

3,053 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+4.06%-40.17%-62.33% 117.82Cr
+1.50%-2.28%-2.46%-23.57% 2.05TCr
+0.40%-0.29%-14.20%-12.31% 1.49TCr
-1.67%-2.67%-59.83%-45.19% 561.55Cr
-0.60%-7.39% - - 368.67Cr
-0.94%-2.42%-19.23%-18.35% 172.81Cr
+2.66%-2.07%+33.94%+11.13% 155.92Cr
-0.86%+5.02%+58.85%+120.77% 83Cr
-3.77%-1.44%+3.67%+129.05% 47Cr
+5.08%-6.69% - - 26Cr
Average +0.22%+0.76%-4.93%+12.40% 507.02Cr
Weighted average by Cap. +0.53%-0.78%-12.29%-18.12%

Financials

2026 *2027 *
Net sales 182.63Cr 27Cr 24Cr 22Cr 20Cr 38Cr 2.57TCr 39Cr 259.64Cr 101.96Cr 1.27TCr 101.13Cr 99Cr 4.35TCr 216.15Cr 32Cr 28Cr 26Cr 24Cr 45Cr 3.04TCr 46Cr 307.31Cr 120.68Cr 1.5TCr 119.7Cr 117.09Cr 5.15TCr
Net income 38Cr 5.65Cr 4.94Cr 4.55Cr 4.21Cr 7.98Cr 538.4Cr 8.12Cr 54Cr 21Cr 265.23Cr 21Cr 21Cr 911.81Cr 48Cr 7.09Cr 6.2Cr 5.72Cr 5.28Cr 10Cr 676.07Cr 10Cr 68Cr 27Cr 333.05Cr 27Cr 26Cr 1.14TCr
Net Debt -35Cr -5.1Cr -4.46Cr -4.11Cr -3.8Cr -7.21Cr -486.16Cr -7.33Cr -49Cr -19Cr -239.5Cr -19Cr -19Cr -823.35Cr -59Cr -8.69Cr -7.6Cr -7.01Cr -6.48Cr -12Cr -829.14Cr -12Cr -84Cr -33Cr -408.46Cr -33Cr -32Cr -1.4TCr
Logo Eyebright Medical Technology (Beijing) Co., Ltd.
Eyebright Medical Technology (Beijing) Co Ltd is a China-based company mainly engaged in the manufacturing of ophthalmic medical devices. The Company's products cover three major areas: ophthalmic surgical treatment, myopia prevention and control, and vision health care. The surgical treatment products mainly include the series of basic and functional artificial intraocular lenses such as Proming and Quanshi. The myopia prevention and control products mainly include iBright brand corneal reshaping lenses, as well as defocusing frame lenses, defocusing soft lenses, and daily rigid contact lenses. The vision health products mainly include transparent contact lenses and colored contact lenses from brands such as Lebleu, Ocula, and TOPPOP.
Employees
2,331
Date Price Change Volume
10/26/10 CN¥41.56 +0.41% 45,46,399
09/26/09 CN¥41.39 +2.78% 55,86,225
08/26/08 CN¥40.27 +3.84% 48,78,072
07/26/07 CN¥38.78 -1.20% 38,12,939
06/26/06 CN¥39.25 -1.73% 34,29,516
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
41.56CNY
Average target price
57.33CNY
Spread / Average Target
+37.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688050 Stock